RT Journal Article
SR Electronic
T1 The COVID-19 Community Research Partnership: Objectives, Study Design, Baseline Recruitment, and Retention
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.09.22270272
DO 10.1101/2022.02.09.22270272
A1 The COVID-19 Community Research Partnership
A1 John Sanders
YR 2022
UL http://medrxiv.org/content/early/2022/02/10/2022.02.09.22270272.abstract
AB The COVID-19 Community Research Partnership (CCRP) is a multisite surveillance platform designed to characterize the epidemiology of the SARS-CoV-2 pandemic. This manuscript describes the CCRP study design and methodology. The CCRP includes two prospective cohorts, one with six health systems in the mid-Atlantic and southern United States, and the other with six health systems in North Carolina. With enrollment beginning April 2020, sites invited persons within their healthcare systems as well as community members to participate in daily surveillance for symptoms of COVID-like illnesses, testing and risk behaviors. Participants with electronic health records were also asked to volunteer data access. Subsets of participants, representative of the general population and including oversampling of populations of interest, were selected for repeated at home serology testing. By October 2021, 65,739 participants (62,261 adult and 3,478 pediatric) were enrolled with 89% providing syndromic data, 74% providing EHR data, and 70% participating in one of two serology sub-studies. An average of 62% of participants completed a daily survey at least once a week, and 55% of serology kits were returned. The CCRP provides rich regional epidemiologic data and opportunities to more fully characterize the risks and sequelae of SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded under the Centers for Disease Control and Prevention (CDC) Contract #75D30120C08405 and by the CARES Act of the US Department of Health and Human Services (HHS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Wake Forest University Health Sciences Institutional Review Board (IRB) School of Medicine was designated as the Central IRB by all agencies participating in the study. The IRB gave approval for this study on 4/6/2020. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the corresponding author.